Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 657-660    DOI: 10.31083/j.ejgo.2020.04.5458
Case Report Previous articles | Next articles
Perivascular epithelioid cell tumor arising in the left parametrium: a case report
Soo-Young Lee1, Dae-Hyung Lee1, *()
1Department of Obstetrics & Gynecology, College of Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea
Download:  PDF(994KB)  ( 223 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
The perivascular epithelioid cell tumors (PEComas) mimic rare epithelial mesenchymal tumors with epithelioid features and perivascular clear cells that co-express the muscle and melanocytic markers. The PEComas include lymphangioleiomyomatosis, clear cell sugar tumor, angiomyolipoma, and myomelanocytic tumors. We report a case involving 37-year-old woman with a PEComa in the left parametrium. The patient was referred to our hospital with an adnexal tumor detected during medical examination. Therefore, she underwent laparoscopic mass excision surgery. Immunohistochemical staining of the tumor cells indicated positivity for Melan A, HMB45, and desmin. Finally, the tumor was diagnosed as a PEComa. The patient is undergoing regular follow-up, and no recurrence has been noted at 2 years after the surgery.
Key words:  Perivascular epithelioid cell tumors      Parametrium      Immunohistochemistry     
Submitted:  06 January 2020      Accepted:  17 June 2020      Published:  15 August 2020     
*Corresponding Author(s):  DAE-HYUNG LEE     E-mail:  leebhy@ynu.ac.kr

Cite this article: 

Soo-Young Lee, Dae-Hyung Lee. Perivascular epithelioid cell tumor arising in the left parametrium: a case report. European Journal of Gynaecological Oncology, 2020, 41(4): 657-660.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.5458     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/657

[1] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[2] Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.
[3] M.H. Hajeer, A. Al Khader, N.A. Shahin, M.S. Bata. Negative p53 expression and negative high risk HPV in a 26-year-old lady with vulvar keratinizing squamous cell carcinoma: report of a case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 130-133.
[4] N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.
[5] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[6] H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.
[7] A.M. Sindiani, M.S. Alorjani, B.K. Aldaraiseh. Dysgerminoma of the ovary in an adolescent girl associated with a high serum β-human chorionic gonadotropin (β-hCG) level[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 859-861.
[8] S. Kabukcuoglu, B. Hayit. Histopathologic features of advanced stage endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 614-618.
[9] Lan Zhong, Feng Deng, Xingsheng Shu, Zhilan Peng. P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 463-467.
[10] H. Cao, S. Yang, S. Xie, M. Xi. The association between p16INK4a and prognosis in endometrial carcinoma: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 311-317.
[11] Xiang Wang, Zhuo Deng, Lijie Wang, He Chen, Huilian Hou, Xu Li. Immunohistochemical analysis of IQGAP2 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 74-79.
[12] Weili He, Hening Zhai, Ningxia Wang. Expression of FOXA1 in breast cancer and the significance[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 97-100.
[13] Z.A. Tas, T. Ozgur, M. Yaldiz, K. Dolapcioglu. MMP7 and YKL-40 expressions in endometrial endometrioid carcinomas[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 123-129.
[14] Xiao Luo, Kui Jiang. The expression and clinical significance of YAP and cIAP1 in ovarian serous adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 130-135.
[15] M. F. Benoit. Surgical staging and differential protein expression in endometrial cancers[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 859-866.
No Suggested Reading articles found!